Adults in the United States with severe mental illness (SMI), such as schizophrenia and bipolar disorder (totaling approximately 7 million), are estimated to die, on average, 25 years earlier than the general population, largely of premature cardiovascular disease. 1 The Institute of Medicine 2 has called for improvements in health care for this population. Severe mental illness is associated with elevated risk for type 2 diabetes mellitus. 3 Treatment with antipsychotic medications contributes to risk, with most evidence focused on second-generation antipsychotic medications, but similar increases in risk are reported with older and newer medications. 4 The American Diabetes Association 5 recommends annual diabetes screening for patients treated with antipsychotic medications, and public health administrators have targeted this population for improved health screening. 6 To our knowledge, no studies have examined screening rates in this highest-risk population of adults with SMI because of limitations in public health medical records. We examined diabetes screening among publicly insured adults with SMI taking antipsychotic medications using matched administrative data for physical and mental health care services in a large health care system. We measured diabetes screening prevalence among patients with SMI treated with antipsychotic medications and assessed characteristics predictive of screening.
Methods | This retrospective cohort study analyzed data from the California Medicaid (Medi-Cal) and Client and Service Information systems using the 2 study periods January 1, 2009, to December 31, 2009 (period 1), and October 1, 2010, to September 30, 2011 (period 2) . Data from period 2 were used to characterize diabetes screening in the subgroup without diabetes mellitus in period 1. Following approval by the UCSF (University of California, San Francisco) Committee of Human Research, the State of California Committee for the Protection of Human Subjects, and the California Department of Health Care Services' Data and Research Committee, the latter department combined these databases, deidentified data, and created our analytic data set. The following criteria characterized the cohort: (1) age 18 years or older, (2) diagnosis of SMI by a psychiatrist, (3) prescription of an antipsychotic medication at least once during period 1 and period 2, (4) mental health care use during both study periods, (5) Medi-Cal enrollee, and (6) non-dual eligibility for Medicare (because of unavailable Medicare laboratory billing data). The primary outcome measure was evidence of diabe-tes screening via glucose-specific fasting serum test (Current Procedural Terminology [CPT] code 82947, 82948, 82950, or 82951) or glycated hemoglobin test (CPT code 83036). A secondary outcome was nonspecific screening (eg, nonfasting metabolic panel) (CPT code 80048, 80050, or 80053) . Poisson regression was used to estimate the relative prevalence of diabetes screening for each predictor. We estimated associations for receiving diabetes-specific screening vs nonspecific or no screening and then contrasted any screening vs none. Using statistical software (Stata, version 13.2; StataCorp LP), robust standard errors were used to account for clustering of outcomes by county and to accommodate the use of a Poisson model for a binary outcome.
Results | Of 50 915 study participants, 15 315 (30.1%) received diabetes-specific screening ( Table 1) . Almost one-third, 15 832 (31.1%), received no form of glucose screening in a yearlong period. The strongest correlate of diabetes-specific screening was having at least 1 outpatient primary care visit during the period examined (adjusted prevalence ratio, 1.80; 95% CI, 1.62-2.00; P < .001) ( Table 2) .
Discussion | In this large cohort study of adults with SMI taking antipsychotic medications in the California public mental health care system, almost 70% were not screened for diabetes mellitus using validated screening measures. Individuals with SMI who had at least 1 primary care visit in addition to mental health services were more than twice as likely to be screened than those who did not. This observation supports the value of burgeoning efforts to integrate behavioral health and primary care. Growing evidence supports the value of screening for diabetes mellitus in higher-risk populations, such as those receiving treatment with antipsychotic medications, including first-generation and second-generation agents that commonly result in co-occurring obesity. Future studies should explore barriers to screening in this vulnerable population. This problem is well illustrated in the study by Mangurian et al 1 in this issue of JAMA Internal Medicine. The authors used California Medicaid data to identify patients who were prescribed an antipsychotic medication. They then assessed what percentage of the patients had some form of glucose screening, a recommendation by the American Diabetes Association 2 for persons taking antipsychotic medications, in a yearlong period. Overall, 30.1% of individuals were screened. It would be fair to point out that the efficacy of screening for diabetes has not been well established. However, that less than one-third had such screening for a known adverse effect of antipsychotic medication use suggests opportunities for improvement in integrated health care. Among those who had at least 1 primary care visit during the year, the proportion screened was significantly higher at 35.6% vs 19.8% for those who had no primary care visit.
To improve care for persons with serious mental illness, it will be necessary to break down the silos that separate the mental health and physical health care systems. Integrated care (care provided by a team of physical and mental health clinicians)-or at least colocated care (care provided by physical and mental health clinicians in the same place)-offers the promise of improving the physical health of individuals with mental illness, as well as the mental health of those seeking physical health services. 
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Use of Intra-aortic Balloon Pump in a Japanese Multicenter Percutaneous Coronary Intervention Registry
We read with interest the recent meta-analysis by Ahmad et al, 1 demonstrating a negative association between intraaortic balloon pump (IABP) therapy and mortality among patients experiencing acute m y o c a r d i a l i n f a r c t i o n . We agree that efforts are needed to clarify the role of IABP therapy and to examine its effect on care in other regions and countries. In Japan, IABP therapy is frequently used in patients with guideline-based indications and in patients with less established indications, and the judicious use of invasive procedures has been highlighted. 2,3 Our objective herein was to investigate the prognostic effect of IABP use in patients undergoing percutaneous coronary intervention (PCI) for nonacute and acute indications registered in a contemporary multicenter Japanese PCI registry (Japan Cardiovascular Database-Keio Interhospital Cardiovascular Studies 4 ).
Methods | We analyzed data from 14 378 consecutive patients treated between September 2, 2008, and May 19, 2014 . Of those, 1124 patients were excluded because of missing baseline information (n = 192), registration for staged PCI during the same hospitalization (n = 801), or PCI performed under percutaneous cardiopulmonary support (n = 132). The remaining 13 253 patients were included herein, and logistic regression models for in-hospital mortality were used to correct for differences in variables. We included in the logistic regression model all variables exhibiting a significant (P < .10) bivariate association with IABP use. Baseline inequality between patients with and without IABPs was evaluated with the baseline inequality index, the same method used by Ahmad et al. 1 Because our study focused on the effect of IABP on in-hospital mortality for all PCIs, we redefined a list of baseline characteristics recognized as markers of mortality risk based on a previous study. 5 Results | Baseline demographics in patients with and without IABPs are summarized in the Table. Overall, PCIs after STsegment elevation myocardial infarctions and PCIs after non-ST-segment elevation myocardial infarctions or unstable angina accounted for 23.9% and 24.2% of the procedures, respectively. Before PCI, 486 patients (3.7%) and 900 patients (6.8%) manifested complications of cardiogenic shock and serious heart failure (New York Heart Association functional classification ≥3), respectively. The proportions of interventions for left main trunk and 3-vessel disease were 3.7% and 0.9%, respectively. Intra-aortic balloon pumps were inserted in 885 patients (6.7%). There were 134 in-hospital deaths (15.1%) among the patients receiving an IABP and 111 inhospital deaths (0.9%) among the patients not receiving an IABP. In the crude analysis, the use of IABP was associated with an increased risk of in-hospital mortality (Figure, A) .
Intra-aortic balloon pump use remained an independent predictor of in-hospital mortality after adjusting for baseline differences (odds ratio, 3.87; 95% CI, 2.71-5.52; P < .001). Among several subgroups thought to potentially have indications for IABP use, the use of IABPs was consistently associated with risk of in-hospital death (Figure, B) , and IABP recipients had a worse baseline risk profile than nonrecipients (Figure, C) . Notably, the risk of death appeared to be higher (with higher odds ratios) as the indications for IABP use became less established.
Discussion | Among a cohort of Japanese patients undergoing PCI in whom IABP use was frequent, we found that the use of IABP was associated with a higher risk of in-hospital death. This
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